Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Gilead Sciences’ antiviral drug candidate remdesivir has led to quick recoveries in symptoms of Covid-19 patients in a clinical trial, according to a report by STAT news agency.
STAT is said to have obtained a copy of a video discussion by a University of Chicago faculty member overseeing the study.
According to the partial data reported, participants treated with remdesivir experienced rapid recoveries in fever and respiratory symptoms and nearly all patients were discharged within one week.
Commenting on the report, Gilead said in an email statement that the clinical data has to be analysed before any conclusions can be drawn.
An email from the University of Chicago Medicine noted: “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions.”
Gilead estimates results from its Phase III trial involving severe Covid-19 patients to be available at the end of this month, while results from other studies are expected in May.
The University of Chicago is one of 152 sites conducting Gilead’s single-arm trial in severe Covid-19 patients. A trial for the treatment of moderate Covid-19 symptoms is said to involve sites.
STAT said that University of Chicago Medicine enrolled a total of 125 patients into two of Gilead’s trials, with 113 of these subjects having severe disease. The majority of patients have been reportedly discharged, while two participants died.
Last week, Gilead reported positive data from analysis of an international cohort of Covid-19 patients treated with remdesivir on an individual compassionate use basis.
According to the data, most patients treated with remdesivir experienced clinical improvement without any new safety signals.
In addition to Gilead’s trials, the drug is being assessed in a Covid-19 study funded by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID).